中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (14) :1147-1150    DOI: 10.11669/cpj.2013.14.003
�� �� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << [an error occurred while processing this directive] | [an error occurred while processing this directive] >>
��ɼ����ҩ�����о���չ���о�����
����γ��³�Ǻ����߾�������*
������ѧ����ҽԺ�߱��������������о������������ڿ�,���������������Ƽ�ת���о��������ص�ʵ����,���� 100142
YU Jing-wei, LU Zhi-hao, GAO Jing, SHEN Lin*
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Download: PDF (613KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �����й���ɼ����ҩ����ػ��Ƽ������о���չ�� ���� �Խ������������о�����Ϊ����,����ɼ���Ľṹ�����������Ƽ�����ҩ��صĿ��ܻ��ƽ����ܽ�������� ��� �ܽ����������ɼ����ҩ��صĶ��ֻ���,�����ط���������ɼ�����û��ƺͰе���ص�β΢�ܵ���III�ͼ�΢�ܽ�ϵ���Tau������ ��ɼ������ҩ���漰�������ء��������,����ҩ���о�Ӧ�ӵ�һ�����о�����������Ϸ���չ,�ۺϿ�����������ָ����ܸ����졢��׼ȷ�Ľ�ʾ��ɼ������ҩ��,�Ӷ������ٴ����廯�����и���һ����ָ����
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
����γ
³�Ǻ�
�߾�
����*
�ؼ����� ��ɼ��   ��ҩ��   ΢�ܽ�ϵ���Tau   β΢�ܵ���III��     
Abstract�� ObjectiveTo review the chemoresistance mechanism of paclitaxel and the latest relevant researches. Methods Based on the newest research reports at home and abroad, the structure, antitumor mechanism and possible resistance mechanisms of paclitaxel were analyzed and summarized. Results Many influencing factors and mechanisms of paclitaxel resistance were summarized, among which, β-tubulin III and microtubule-associated proteins Tau were laid special stress on. Conclusion Many factors and mechanisms are involved in the resistance of paclitaxel. In order to improve the specificity and accuracy, multiple possible factors and mechanisms should be considered, rather than one factor or one biomarker. Only in this way, can we achieve the individualized treatment of paclitaxel in clinic.
Keywords�� paclitaxel,   chemoresistance,   microtubule-associated proteins Tau,   β-tubulin III     
�ո�����: 2012-08-01;
��������:

������Ŀ:������Ȼ��ѧ����������Ŀ(81172110)

ͨѶ���� ����,Ů,����,��ʿ����ʦ,����ҽʦ �о�����θ�����������廯���μ�ת���о� Tel(010)88196747 E-maillin100@medmail.com.cn     Email: lin100@medmail.com.cn
���߼��: ����γ,��,��ʿ�о��� �о�����θ���ĸ��廯����
���ñ���:   
����γ, ³�Ǻ�, �߾��� .��ɼ����ҩ�����о���չ���о�����[J]  �й�ҩѧ��־, 2013,V48(14): 1147-1150
YU Jing-Wei, LU Zhi-Hao, GAO Jing etc .Research Progress in Chemoresistance Mechanism of Paclitaxel and the Future Direction[J]  Chinese Pharmaceutical Journal, 2013,V48(14): 1147-1150
��
[1] PEI B X, SUN Y S, DONG S H, et al. Curative effect of Abraxane in patients with Non-small-cell lung cancer and breast cancer . Chin Pharm J (�й�ҩѧ��־), 2011, 46(23): 1851-1854.
[2] SAKAMOTO J, MATSUI T, KODERA Y. Paclitaxel chemotherapy for the treatment of gastric cancer .Gastric Cancer, 2009, 12(2): 69-78.
[3] WANI M C, TAYLOR H L, WALL M E, et al. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia . J Am Chem Soc, 1971, 93(9): 2325-2327.
[4] ROWINSKY E K, DONEHOWER R C. Paclitaxel (taxol) . N Engl J Med, 1995, 332(15): 1004-1014.
[5] ELOMAA L, JOENSUU H, KULMALA J, et al. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer . Acta Oto-Laryngol, 1995, 115(2): 340-344.
[6] ZHOU W J, LIU T, CHEN Q C, et al.Kill effect of two different formulations paclitaxel in KB cell in vitro. Chin Pharm J (�й�ҩѧ��־), 2012, 47(6): 439-443.
[7] SZAK�jCS G, PATERSON J K, LUDWIG J A, et al. Targeting multidrug resistance in cancer . Nat Rev Drug Discov, 2006, 5(3): 219-234.
[8] GONZALEZ-GARAY M L, CHANG L, BLADE K, et al. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance . J Biol Chem, 1999, 274(34): 23875-23882.
[9] ORR G A, VERDIER-PINARD P, MCDAID H, et al. Mechanisms of taxol resistance related to microtubules .Oncogene, 2003, 22(47): 7280-7295.
[10] URANO N, FUJIWARA Y, HASEGAWA S, et al. Absence of beta-tubulin gene mutation in gastric carcinoma . Gastric Cancer, 2003, 6(2): 108-112.
[11] VERDIER-PINARD P, PASQUIER E, XIAO H, et al. Tubulin proteomics: Towards breaking the code. Anal Biochem, 2009, 384(2): 197-206.
[12] KAVALLARIS M. Microtubules and resistance to tubulin-binding agents . Nat Rev Cancer, 2010, 10(3): 194-204.
[13] PANDA D, MILLER H P, BANERJEE A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition . Proc Nati Acad Sci USA, 1994, 91(24): 11358-11362.
[14] AZUMA K, SASADA T, KAWAHARA A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel . Lung Cancer, 2009, 64(3): 326-333.
[15] S�GVE P, REIMAN T, DUMONTET C. The role of III tubulin in predicting chemoresistance in non-small cell lung cancer . Lung Cancer, 2010, 67(2): 136-143.
[16] OHISHI Y, ODA Y, BASAKI Y, et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma . Gynecol Oncol, 2007, 105(3): 586-592.
[17] HETLAND T E, HELLESYLT E, FLORENES V A, et al. Class III -tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance .Hum Pathol, 2011, 42(7): 1019-1026.
[18] HASEGAWA S, MIYOSHI Y, EGAWA C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta -tubulin isotype mRNA expression in human breast cancers .Clin Cancer Res, 2003, 9(8): 2992-2997.
[19] TOMMASI S, MANGIA A, LACALAMITA R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins . Int J Cancer, 2007, 120(10): 2078-2085.
[20] S�GVE P, REIMAN T, LAI R, et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site . Cancer Chemoth Pharm, 2007, 60(1): 27-34.
[21] URANO N, FUJIWARA Y, DOKI Y, et al. Clinical significance of class III beta -tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer . Int J Oncol, 2006, 28(2): 375-381.
[22] PLOUSSARD G, TERRY S, MAILL��P, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy . Cancer Res, 2010, 70(22): 9253-9264.
[23] HONORE S, PASQUIER E, BRAGUER D. Understanding microtubule dynamics for improved cancer therapy . Cell Mol Life Sci, 2005, 62(24): 3039-3056.
[24] HAMPEL H, BLENNOW K, SHAW L M, et al. Total and phosphorylated tau protein as biological markers of Alzheimer′s disease . Exp Gerontol, 2010, 45(1): 30-40.
[25] MCGROGAN B T, GILMARTIN B, CARNEY D N, et al. Taxanes, microtubules and chemoresistant breast cancer . Biochim Biophys Acta, 2008, 1785(2): 96-132.
[26] ROUZIER R, RAJAN R, WAGNER P, et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer . P Natl Acad Sci USA, 2005, 102(23): 8315-8320.
[27] TANAKA S, NOHARA T, IWAMOTO M,et al.Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.Cancer Chemoth Pharm, 2009, 64(2): 341.
[28] MIMORI K, SADANAGA N, YOSHIKAWA Y, et al. Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment . Br J Cancer, 2006, 94(12): 1894-1897.
[29] LEONARD G D, FOJO T, BATES S E. The role of ABC transporters in clinical practice . Oncologist, 2003, 8(5): 411-424.
[30] KAMAZAWA S, KIGAWA J, KANAMORI Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer . Gynecol Oncol, 2002, 86(2): 171-176.
[31] MOZZETTI S, FERLINI C, CONCOLINO P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients . Clin Cancer Res, 2005, 11(1): 298-305.
[32] HALDAR S, CHINTAPALLI J, CROCE C M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells . Cancer Res, 1996, 56(6): 1253-1255.
[33] BASU A, DUBOIS G, HALDAR S. Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy . Front Biosci, 2006, 11(1): 1508-1521.
[34] BLAGOSKLONNY M V, SCHULTE T, NGUYEN P, et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway . Cancer Res, 1996, 56(8): 1851-1854.
[35] BHALLA K N. Microtubule-targeted anticancer agents and apoptosis . Oncogene, 2003, 22(56): 9075-9086.
[36] SHITASHIGE M, TOI M, YANO T, et al. Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2 . J Biochem, 2001, 130(6): 741-748.
[37] YIP K W, REED J C. Bcl-2 family proteins and cancer . Oncogene, 2008, 27(50): 6398-6406.
[38] CHO H J, KIM J K, KIM K D, et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells . Cancer Lett, 2006, 237(1): 56-66.
[39] MICHAUD W A, NICHOLS A C, MROZ E A, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma . Clin Cancer Res, 2009, 15(5): 1645-1654.
[40] AOKI D, ODA Y, HATTORI S, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma . Clin Cancer Res, 2009, 15(4): 1473-1480.
[41] BAQUERO M T. Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer. J Clin Oncol, 2010 ASCO Aunual Meeting Proceedings, 2010: 10523.
[1] ����*�����������е�Ϊ*��������������*��¬�,*.��ɼ��������ҩ��ѧ����Ե����ͷ���[J]. �й�ҩѧ��־, 2013,48(7): 546-552
[2] ����,,�����,,,����ϼ,,,��С��,����,,,κ��,,,���,,*.��ɼ��֬������Ʊ����������ԡ�ҩЧѧ�о�[J]. �й�ҩѧ��־, 2013,48(6): 446-449
[3] ��һľ,������,�����*.��ɼ����Ͻ������Ʊ�����������峦����[J]. �й�ҩѧ��־, 2013,48(13): 1076-1082
[4] ����ݼ ��� ��ٻ�� ���� ������ �ƺ�� .���ֲ�ͬ������ɼ����KBϸ��������ɱ������[J]. �й�ҩѧ��־, 2012,47(6): 439-443
[5] ���� ������ ���ܻ� ������ ̷���� �⴫��.�ζ���˨����ԭλֲ������Һ�������ͷ���Ϊ���о�[J]. �й�ҩѧ��־, 2012,47(3): 213-
[6] �춬����ΰ����骣������ڣ�÷�˹�������ǿ.��ЧҺ��ɫ��-������Դ-�������÷��ⶨ��ɼ������֬���弰���������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2012,47(22): 1839-1843
[7] ����ɣ���־�������ң��*.pH��Ӧ���׵�ҩϵͳ����ת������ҩ��ҩ�Է�����о���չ[J]. �й�ҩѧ��־, 2012,47(20): 1609-1613
[8] ���٣�������.��ŵ��Τ�������������͸����ٴ��о�[J]. �й�ҩѧ��־, 2012,47(18): 1449-1452
[9] ���٣��쿡�������£�������������.�Ǿ�����ϩȫ�ܱ���Һ����Ͳ���ƿ�뿹����ҩ��������ԱȽ��о�[J]. �й�ҩѧ��־, 2012,47(18): 1521-1521
[10] ��С�ģ���������Ӧ����.��Ժ�º�������Ⱦ����������ҩ���о�[J]. �й�ҩѧ��־, 2012,47(17): 1418-1419
[11] ̷٩;�˱���;�ݺ���.����������Ϊһ����ҩ�����ѳ����ķ���Ч������[J]. �й�ҩѧ��־, 2012,47(11): 870-871
[12] �ƽa;Ҷ��a;���·�b;¥�;��ѧ��a;������;����ǿc;��־��d.2009~2010���㽭��ѧ��ͯҽԺ�����������ҩ�Ժ�Ѫ�����[J]. �й�ҩѧ��־, 2012,47(10): 792-795
[13] ����Ƽ.Ӧ�ûƽ������о�����ҩ�ﲻ����Ӧ�ͽ�����ҩ�Եķ���[J]. �й�ҩѧ��־, 2012,47(10): 785-788
[14] �Թ�ΰ;ʷ¼��.̱������ҽԺ��Ⱦ����о�������ҩ�����Ʒ���̽��[J]. �й�ҩѧ��־, 2012,47(10): 838-840
[15] ��ѧ�� ������ ����» ë���� ���� ������.��ɼ�����׻��������Ʊ������ڶ�������ҩ��ѧ����֯�ֲ��о�[J]. �й�ҩѧ��־, 2011,46(9): 680-685
Copyright 2010 by �й�ҩѧ��־